DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Insecticides India Q2FY27 Results: Earnings call scheduled for Nov 5

scanx.trade 1 hr ago·7 Oct 2026, 6:40 am

Insecticides India has announced its results for the second quarter of fiscal year 2027, following which the company will hold an earnings call on November 5. While the specific financial figures for the quarter have not been released at this time, the announcement signals that the company is preparing to discuss its performance with investors and analysts.

This earnings call is a key opportunity for the company to provide clarity on its business trajectory, operational efficiency, and future outlook. For investors, it offers a chance to understand how the company is navigating the current market environment and what strategies it plans to implement moving forward.

Investors should watch for updates on sales volumes, margin trends, and management commentary on demand conditions. This information will be crucial for assessing the company's current health and its potential for growth in the coming quarters.